016580 — Whanin Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapContrarian

Annual income statement for Whanin Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	159,177	171,705	177,776	198,935	230,394
Cost of Revenue
Gross Profit	79,181	86,602	93,492	98,793	99,161
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	133,012	143,287	146,500	169,124	200,223
Operating Profit	26,165	28,418	31,276	29,810	30,170
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	28,222	31,082	33,882	29,808	33,793
Provision for Income Taxes
Net Income After Taxes	18,612	23,191	26,459	23,734	29,774
Minority Interest
Net Income Before Extraordinary Items
Net Income	18,696	23,388	26,660	23,921	29,774
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	18,696	23,388	26,660	23,921	29,774
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,255	1,535	1,747	1,666	2,017
Dividends per Share